Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.6MCash on Hand
6.4mo Cash Runway
Follow ZSTK by emailGet an email when ZSTK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ZSTK, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Leadership ZeroStack dismissed auditor Davidson & Company, LLP on November 5, 2026, after its interim review remained incomplete pending supporting documentation for certain transactions. L J Soldinger Associates was appointed November 6 to review Q3 2026 and audit fiscal 2026. Form 8-K · SEC filing
Nov 9, 2026 ·
Deal ZeroStack agreed on November 3, 2026 to sell all shares of its Phatebo GmbH subsidiary to New Horizon Pharma B.V. for €2,150,000. Closing requires German foreign direct investment clearance and other conditions. Form 8-K · SEC filing
Nov 2, 2026 ·
Leadership ZeroStack entered a consulting agreement with CFO Dany Vaiman and Summer 366 Holdings LLC, effective November 1, 2026, with a twelve-year term, a US$350,000 base fee and a target bonus of US$350,000 per year each. The prior Vaiman employment agreement was terminated, though Vaiman remains sole CFO. Form 8-K · SEC filing
Aug 26, 2026 ·
Financing ZeroStack filed a shelf registration statement to sell up to $1,000,000,000 of common stock, warrants, rights, subscription receipts, preferred stock, debt securities and units from time to time. Specific offering amounts, prices and terms will be set in future prospectus supplements. Form S-3 · SEC filing
Aug 21, 2026 ·
Financing ZeroStack filed a registration statement covering resale of 54,609,992 common shares by selling securityholders, with no proceeds going to the company. The shares were issued or are issuable in a private placement and option awards. Nasdaq last price cited was $4.96 on August 19, 2026. Form S-3 · SEC filing
Aug 21, 2026 ·
ZeroStack Corp. states that the disclosure in this Item 8.01 was previously included in its Form S-3 registration statement filed August 21, 2026, and that it supplements prior disclosures including its 2025 Form 10-K and quarterly reports for March 31 and June 30, 2026. Form 8-K · SEC filing
Aug 19, 2026 ·
Deal ZeroStack agreed to issue 3,500,000 common shares and pre-funded warrants for up to 36,198,293 more shares at $25.19 each, in exchange for 925,925,926 M tokens valued at about $1 billion. Warrant shares await shareholder approval under Nasdaq Rule 5635. Rudy Rong, a Memecore principal, is being appointed President. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
ZSTK holds $2.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.2M/quarter from operations,
an estimated runway of 6.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:60 · High
Cash runway 6 months +30
ATM program on file since Sep 2025 +15
Shelf registration (S-3, Aug 2026) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.10-Q, Jul 2026
Raised after last reported balance sheet (Aug 2026) -10
Share count 17,489,828 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ZSTK picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZSTK and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.